A previous randomised-controlled trial (RCT) in individuals with treatment-resistant depression investigated the efficacy of infliximab, a monoclonal antibody for TNF-α, in the reduction of depressive symptoms [64]. The gene discussed is TNF; the disease is major depressive disorder.